HCP MANAGEMENT GUIDE

Including important safety information to minimise the risk of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

This follow-up guidance is supplemental to the obecabtagene autoleucel UK Summary of Product Characteristics (SPC) and is based on ASTCT / ASBMT* guidelines for CAR T Adverse Events Management for CRS and ICANS.

* ASTCT/ASBMT = American Society for Transplantation and Cellular Therapy/ American Society for Blood and Marrow Transplantation Consensus Grading

Patient Card for Aucatzyl

This medicine is subject to additional monitoring.

This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Have this card with you at all times. Show it to any hospital you visit and healthcare providers who see you

and tell them that you are being treated with autologous T-cell immunotherapy.